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Abstract
Purpose: Our purpose was to describe the risk of radiation-induced brachial plexopathy (RIBP) in patients with breast cancer who
received comprehensive adjuvant radiation therapy (RT).
Methods and Materials: Records for 498 patients who received comprehensive adjuvant RT (treatment of any residual breast tissue, the
underlying chest wall, and regional nodes) between 2004 and 2012 were retrospectively reviewed. All patients were treated with
conventional 3 to 5 field technique (CRT) until 2008, after which intensity modulated RT (IMRT) was introduced. RIBP events were
determined by reviewing follow-up documentation from oncologic care providers. Patients with RIBP were matched (1:2) with a control
group of patients who received CRT and a group of patients who received IMRT. Dosimetric analyses were performed in these patients
to determine whether there were differences in ipsilateral brachial plexus dose distribution between RIBP and control groups.
Results: Median study follow-up was 88 months for the overall cohort and 92 months for the IMRT cohort. RIBP occurred in 4 CRT
patients (1.6%) and 1 IMRT patient (0.4%) (P Z .20). All patients with RIBP in the CRT cohort received a posterior axillary boost.
Maximum dose to the brachial plexus in RIBP, CRT control, and IMRT control patients had median values of 56.0 Gy (range, 49.7-
65.1), 54.8 Gy (47.4-60.5), and 54.8 Gy (54.2-57.3), respectively.
Conclusions: RIBP remains a rare complication of comprehensive adjuvant breast radiation and no clear dosimetric predictors for RIBP
were identified in this study. The IMRT technique does not appear to adversely affect the development of this late toxicity.
 2020 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Patients with locally advanced breast cancer often
require treatment with a combination of surgery, chemo-
therapy, and comprehensive adjuvant radiation therapy
(RT), which we operationally define as treatment to any
residual breast tissue, the chest wall, and the regional
lymph nodes. Historically, comprehensive adjuvant RT at
our institution was delivered using opposed tangent fields
along with a matched supraclavicular field. Internal
mammary lymph nodes (IMLNs) were routinely treated
via partially deep tangents or a separate IMLN field.1
Additionally, a posterior axillary boost (PAB) field was
often used. With the use of computed tomography-based
simulation, newer techniques such as inverse planning
intensity modulated radiation therapy (IMRT) have
emerged to aid in delivering comprehensive adjuvant ra-
diation treatments.2
With improving local and systemic treatments, a sig-
nificant proportion of patients receiving comprehensive
RT achieve long-term survival.3 As a result, toxicity from
RT is of substantial concern in this population. Chronic,
rare toxicities such as radiation-induced brachial plexop-
athy (RIBP) have previously been associated with con-
ventional RT to the breast and regional lymph nodes.4-6
Therapy-related complications involving the upper ex-
tremity negatively affect patient quality of life.7 However,
studies evaluating long-term toxicities in patients
receiving comprehensive RT with modern techniques are
lacking. We identified patients with breast cancer treated
at our institution with conventional RT (CRT) or IMRT
techniques for comprehensive adjuvant RT and reported




We reviewed the medical records of patients with
breast cancer treated at our institution with comprehensive
adjuvant RT between 2004 and 2012. All patients were
adults older than 18 years of age. The study was approved
by the institutional review board.
Radiation therapy
Comprehensive adjuvant RT was defined as treatment to
any residual breast tissue, the underlying chest wall, IMLN,
axillary lymph nodes, and supraclavicular lymph nodes
(SCVs). CRT was exclusively used to deliver radiation
between 2004 and 2007. In 2008, IMRT became an option
for delivering comprehensive treatments, with over 50% of
patients receiving IMRT that year. By 2011, more than
90% of patients were treated with IMRT, and the current
standard of practice at our institution is to use IMRT for all
patients receiving comprehensive adjuvant RT.
For the CRT technique, patients were simulated in the
supine position with both arms above their heads using a
slant board. Radiation to the residual breast tissue and
chest wall was delivered with opposed tangential fields.
The table and collimator were optimized to eliminate
divergence superiorly. The SCV fields were directed in an
anterior-posterior direction with a slight oblique angle to
avoid beam exit through the spinal cord and central neck
structures. This field was matched via a half-beam block
to the superior border of the tangential fields. IMLNs were
routinely treated to the first 3 intercostal spaces using
partially deep tangents or a separate IMLN field. Some
patients also received an additional dose with a PAB field
for risk factors such as nodal extracapsular extension or
when dose to the axillary midplane was below 50 Gy.
Weekly MV imaging was performed for treatment set-up
verification.
For IMRT, patients were simulated in the supine posi-
tion with both arms up above their heads using either an
alpha cradle or slant board. The clinical residual breast
tissue, chest wall, and regional nodes were contoured as a
single volume. Medial and lateral SCVs, interpectoral
nodes, axillary nodes, and IMLNs from the first 3 inter-
costal spaces were included in the treatment volume for all
IMRT patients. These target volumes are similar to those
described by DeSelm and colleagues.8 If IMLN involve-
ment was noted on imaging, then all IMLN spaces were
included in the treatment volume. Generally, patients were
treated with 10 or more beam angles spaced approximately
20 to 30 apart. Daily cone beam computed tomography
(CBCT) was used for treatment set-up.
RT courses were delivered using photons with the
option of using electrons for boost treatments or for at
least two-thirds of the IMLN fields for CRT patients. For
all patients, median delivered dose and fractionation for
breast and chest-wall was 50.4 Gy (range, 37.8e55.8) in
1.8 to 2 Gy/fraction, and median delivered dose and
fractionation for SCV nodal region was 50.4 Gy (range,
37.8e58.0) in 1.8 to 2 Gy/fraction. Only 4 patients (2
patients each in the CRT and IMRT cohorts) received
prescription doses higher than 50.4 Gy to the breast or
chest wall volume. Higher doses were used in some
treatment courses before 2010 to address risk factors such
as lymphovascular space invasion and grade 3 disease as
per physician discretion. One patient declined to complete
the entire course of RT and received 37.8 Gy out of the
planned 50.4 Gy.
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Study endpoints and statistical analysis
Brachial plexopathy was defined as chronic symptoms
of paresthesia, numbness, and/or weakness in the ipsi-
lateral arm beginning after completion of RT. Imaging
and electromyography (EMG) studies were reviewed, if
available. Patients who developed brachial plexopathy
secondary to tumor recurrence based on imaging or
demonstrated symptoms before completion of RT were
not classified as patients with RIBP. Time to RIBP was
calculated from completion date of RT course. All pa-
tients underwent follow-up evaluation with a radiation
oncologist, medical oncologist, breast surgeon, physical
medicine and rehabilitation physicians, or other providers.
Matched control cohorts of patients without RIBP
were identified using exact matching in a 1:2 fashion
using patient characteristics of age at completion of RT
(within 10 years), receiving axillary lymph node dissec-
tion (ALND) or not, breast conserving surgery or mas-
tectomy, and dose to SCVs (within 10 Gy).
Chemotherapy was not used as a matching criterion, as
the ultimate purpose of matching was to identify patients
for the dosimetric analysis of brachial plexus dose
distribution.
Separate control cohorts were created for patients
receiving CRT and IMRT. RT plans for patients with
RIBP and matched control patients were retrieved for
dosimetric analysis. The ipsilateral brachial plexus was
not routinely contoured during RT planning at our insti-
tution and thus, this structure was retrospectively con-
toured by a single radiation oncologist on the unarchived
treatment plans according to the Radiation Therapy
Oncology Group guidelines.9 Dosimetric data extracted
from plans included mean dose (Dmean), maximum dose
(Dmax), V40 Gy (volume of brachial plexus receiving 40
Gy or higher), V45 Gy, V50 Gy, and V55 Gy for the
ipsilateral brachial plexus.
Statistical analysis was performed using Statistical
Package for the Social Sciences version 23 (IBM Corp.,
Armonk, NY). Baseline patient characteristics were
compared using Mann-Whitney U-test and c2 test (Fisher
exact test for small cell counts) for continuous and cate-
gorical variables, respectively.
Results
A total of 498 patients met criteria for inclusion in our
study, with 501 breast cancers treated with comprehensive
adjuvant RT. Our cohort included 3 patients who received
bilateral comprehensive adjuvant RT. The CRT technique
was used to treat 243 cases and the IMRT technique was
used to treat 258 cases. Median follow-up was 88 months
in the overall cohort (80 months in the CRT group vs 92
months in the IMRT group). Rates of breast conserving
therapy decreased from 45% in 2004 to 24% in 2012.
Seven patients did not receive any primary breast surgery
and received definitive chemotherapy and RT (4 patients
had occult primaries for which surgery was not per-
formed, 2 patients declined surgery, and 1 patient was
medically inoperable). Three patients were staged as
clinical T0 but had pathologic findings in the surgically
removed breast and nodal tissue that required compre-
hensive adjuvant RT. Rates of ALND did not differ
significantly between the groups and remained similar
throughout the study period from 2004 (84%) to 2012
(80%). Complete baseline characteristics are provided in
Table 1.
Clinical signs and symptoms of brachial plexopathy
were noted in 7 patients. Tumor involvement of the
ipsilateral brachial plexus was identified in 1 patient and
another patient developed brachial plexopathy before
completion of RT presumably secondary to axillary
dissection. As a result, 5 patients were determined to have
RIBP. None of the 4 patients who received a prescription
dose greater than 50.4 Gy to the breast or chest wall
developed RIBP during follow-up. All patients with RIBP
presented with weakness in the ipsilateral arm while 3
patients also presented with paresthesia. The location of
the plexopathy was corroborated with EMG studies and
found in the C5 to 6 trunk for 1 patient and C8eT1 trunk
for 2 patients. The other 2 patients with RIBP did not
receive an EMG evaluation. All patients with RIBP
received physical therapy and patients were also pre-
scribed gabapentin to manage symptoms. Median time to
development of RIBP was 45 months (range, 19-127
months). Four patients who received CRT (1.6%) and 1
patient who received IMRT (0.4%) developed RIBP
(Fisher exact P Z .20) at time of analysis. The matched
control groups consisted of 10 CRT patients and 10 IMRT
patients. Patient and treatment characteristics for RIBP
and matched control patients are listed in Table 2.
Treatment plans were available and analyzed in all pa-
tients with RIBP, and all matched control patients with
dosimetric characteristics are reported in Table 3. The
median Dmean and Dmax to the brachial plexus of patients
with RIBP were 46.7 Gy and 56.0 Gy, respectively.
Median brachial plexus Dmean and Dmax in the CRT
matched cohort were 40.0 Gy and 54.8 Gy, respectively.
Median Dmean and Dmax in the IMRT matched cohort
were 44.1 Gy and 54.8 Gy, respectively.
Discussion
Development of upper extremity toxicities such as
lymphedema and brachial plexopathy from breast cancer
therapy can have deleterious effects on patient quality of
life.7 As modern techniques of RT delivery such as IMRT
are introduced to the clinic, it is important to identify their
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effect on normal tissue toxicity outcomes. To our
knowledge, this is the first study to evaluate the risk of
RIBP in patients receiving comprehensive adjuvant RT
with IMRT.
When our study cohort was stratified by RT technique,
there was no significant difference in rate of RIBP
development between patients receiving CRT or IMRT.
Another modern case series reported a RIBP rate of
0.48% in a cohort of 629 patients with breast cancer
receiving chest wall and ipsilateral SCV radiation with the
CRT technique where the average Dmean and Dmax to the
brachial plexus in patients with RIPB were 47 Gy and 59
Gy, respectively.5 Historical data on the development of
brachial plexopathy in a large cohort of patients with early
stage breast cancer by Pierce et al10 reported a RIBP rate
of 1.8% in patients receiving SCV radiation, 1.3% in
patients with axillary dose of 50 Gy, 5.6% in patients with
axillary dose > 50 Gy, and increased risk of RIBP with
use of chemotherapy. In our study, all patients with RIBP
in the CRT group received PAB, and 4 out of 5 patients
with RIBP received adjuvant chemotherapy. The combi-
nation of surgery and RT to the axilla may also increase
the risk of brachial plexopathy as 4 out of 5 patients with
RIBP received ALND. In support of this argument,
Lundstedt et al11 reported brachial plexopathy symptoms
of paresthesia and weakness in 6.3% of patients treated
with ALND and regional nodal RT, 3.8% of patients with
ALND alone, and 2.7% of patients with no axillary
therapy. The CRT and IMRT cohorts in this study had
similar rates of chemotherapy use and ALND, indicating
that both groups had comparable baseline risk for devel-
oping RIBP.12 One patient with RIPB in our study did not
receive ALND or adjuvant chemotherapy and had the
lowest Dmean and Dmax of all patients with RIPB, sug-
gesting that other patient-intrinsic factors may affect
susceptibility. These findings suggest a multifactorial
etiology for brachial plexopathy after oncologic treat-
ments in patients with breast cancer. Of note, median time
to RIBP in the literature ranges from 1 to 4 years after RT,
which is within the median follow-up obtained for this
study.6 These data show that RIBP remains a rare event
after comprehensive adjuvant RT, and RIBP incidence
does not appear to be increased with use of IMRT.
Standard RT prescription doses for comprehensive
adjuvant treatments fall within brachial plexus dose limits
recommended in the literature.13 With use of boost fields
and patient anatomic variance, brachial plexus dose dis-
tribution may exceed those limits in certain cases, which
hypothetically could result in RIBP. To investigate this
possibility, we performed dosimetric analysis of treatment
plans of patients with RIPB and matched control patients.
Dmean, Dmax, and dose distribution for the contoured
brachial plexus structures did not demonstrate clinically
meaningful differences between patients with RIPB and
matched control patients. Control IMRT patients had
similar Dmean and Dmax values compared with CRT pa-
tients although V50 Gy was relatively higher. A similar
dosimetric analysis by Wu et al5 also did not identify any
relationship between brachial plexus Dmax and RIBP; all
patients in their study were treated with CRT. Lundstedt
et al14 identified a dose-volume relationship for the
brachial plexus (V40 Gy > 13.5 cm3) that resulted in
significant increase in patient-reported paresthesia,
although they cautioned against the use of this association
Table 1 Baseline patient, tumor, and treatment characteristics
Characteristic Overall (n Z 501) CRT (n Z 243) IMRT (n Z 258) P value
Median age (in years) at
completion of RT [range]
53 [25-89] 53 [25-89] 52 [27-86] .67















BCT 178 (36) 97 (40) 81 (31) .09
Mastectomy 316 (63) 144 (59) 172 (67)
Not performed 7 (1) 2 (1) 5 (2)
ALND performed 424 (85) 212 (87) 212 (82) .12







Chemotherapy 466 (93) 226 (93) 240 (92) .99
Hormone therapy received 344 (69) 162 (67) 182 (71) .35
Posterior axillary boost 130 (26) 130 (53) 0 N/A
Abbreviations: ALND Z axillary lymph node dissection; BCT Z breast conserving therapy; CRT Z conventional RT; ERþ Z estrogen receptor
positive; HER2þ Z Her-2-neu receptor positive; IMRT Z intensity modulated RT; LNs Z lymph nodes; RT Z radiation therapy.
* Data missing for some patients (ER and HER2 status were missing for 2 patients in the CRT cohort. Data on number of LNs examined were
missing for 4 patients in the CRT cohort and 1 patient in the IMRT cohort).
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due to lack of symptom confirmation with EMG studies.
Modern image guided RT likely had a role in minimizing
RIBP. Topolnjak and colleagues15 demonstrated the value
of CBCT in reducing daily setup errors in the treatment of
patients with breast cancer with RT. We postulate that the
use of daily CBCT during IMRT may have contributed to
better set-up and dose delivery, and therefore mitigated
the risk of RIBP.
Development of RIBP portends a lifelong complica-
tion, as the symptoms rarely completely resolve and the
risk of developing this toxicity does not decrease with
time.16 Work-up for RIBP should include imaging to rule
out tumor involvement of the brachial plexus. In partic-
ular, magnetic resonance imaging can help rule out tumor
involvement as etiology of symptoms and may also help
localize the plexopathy lesion.17 Magnetic resonance
Table 2 RIBP and matched control baseline characteristics
RIBP patients














A 64 No No None CRT 45 40.5 Yes Yes 6 3.37
B 62 No Yes Adjuvant AC-TH CRT 50.4 50.4 No Yes 6 4.50
C 54 No Yes Adjuvant AC-TH CRT 50.4 50.4 No Yes 10 5.06
D 33 No Yes Adjuvant AC-T CRT 50.4 50.4 No Yes 6 3
E 62 No Yes Adjuvant AC-T IMRT 50.4 50.4 N/A N/A N/A N/A
Matched 3D-CRT control patients














A1 61 No No Neoadjuvant AC-TH CRT 50.4 50.4 Yes No 10 3.96
A2 62 No No Neoadjuvant AC-TH CRT 50.4 50.4 No No 6 5.82
B1 57 No Yes Neoadjuvant and adjuvant HT CRT 50.4 50.4 No No 6 3.2
B2 54 No Yes Adjuvant AC-T CRT 50 46 Yes Yes 6 3.09
C1 50 No Yes Neoadjuvant herceptin,
vinorelbine, and doxorubicin
CRT 50.4 50.4 No Yes 6 3
C2 45 No Yes Adjuvant AC-T CRT 50.4 50.4 Yes Yes 6 2.9
D1 30 No Yes Neoadjuvant and adjuvant HT CRT 54 54 No Yes 6 3.0
D2* 31 No Yes Neoadjuvant FEC-T CRT 50 46 Yes No 10 d
E1 58 No Yes Adjuvant AC-T CRT 50.4 50.4 No Yes 10 3.7
E2 68 No Yes Neoadjuvant FEC-T CRT 50 46 Yes Yes 6 4.7
Matched IMRT control patients

















AA1 64 No No Adjuvant FEC-T IMRT 50.4 50.4 N/A N/A N/A N/A
AA2 67 No No Adjuvant FEC-T IMRT 50.4 50.4 N/A N/A N/A N/A
BB1 64 No Yes Neoadjuvant AC-T IMRT 50.4 50.4 N/A N/A N/A N/A
BB2 67 No Yes Adjuvant TCH IMRT 50.4 50.4 N/A N/A N/A N/A
CC1 56 No Yes Neoadjuvant FEC-TH IMRT 50.4 50.4 N/A N/A N/A N/A
CC2 49 No Yes Adjuvant FEC-T IMRT 50.4 50.4 N/A N/A N/A N/A
DD1 42 No Yes Adjuvant FEC-TH IMRT 50.4 50.4 N/A N/A N/A N/A
DD2 42 No Yes Neoadjuvant FEC-T IMRT 50.4 50.4 N/A N/A N/A N/A
EE1 53 No Yes Neoadjuvant taxotere,
cytoxan
IMRT 50.4 50.4 N/A N/A N/A N/A
EE2 62 No Yes Adjuvant AC-T IMRT 50.4 50.4 N/A N/A N/A N/A
Abbreviations: 3D-CRT Z 3-dimensional conventional RT; AC-T(H) Z adriamycin, cytoxan, taxol, (herceptin); ALND Z axillary lymph node
dissection; BCT Z breast conserving therapy; CRT Z conventional RT; FEC-T(H) Z fluorouracil, epirubicin, cytoxan, taxotere, (herceptin); HT Z
hormone therapy; IM Z internal mammary; IMRT Z intensity modulated RT; PAB Z posterior axillary boost; RIBP Z radiation-induced brachial
plexopathy; RT Z radiation therapy; SCV Z supraclavicular nodal region.
Two control patients were matched to each radiation-induced brachial plexopathy (RIBP) patient. Control patients A1 and A2 are matched to RIBP
patient A and so on for the remainder of the table.
* Data missing for patient D2.
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imaging in our patients who developed RIBP showed no
tumor in the region of the brachial plexus but did not
always clearly identify the anatomic location of the
plexopathy lesion. On the other hand, EMG can be used
to identify the affected region of the brachial plexus.
Although no clear dosimetric properties are known to
predict RIBP, clinical factors such as aggressive axillary
surgery and RT are known to increase the risk of this
toxicity. Current treatment options for RIBP provide
symptom management but no definite cure.6 Medical
management with gabapentin, pregabalin, opioid, and
nonopioid analgesics is often used in conjunction with
physical therapy (as was recommended to all our patients
with RIPB) to improve neuropathic symptoms and
weakness, respectively.
There are fundamental limitations to the conclusions
that can be drawn from this analysis. Retrospective study
design inherently leads to the possibility of patient se-
lection bias and incomplete collection of toxicity data.
However, the outcome of interest in this study is a chronic
and progressive toxicity that is likely to be noted by care
providers or patients during follow-up visits. Only 5 pa-
tients in our cohort developed RIBP, which limited sta-
tistical analyses. We also note that follow-up for the CRT
cohort was shorter than the IMRT cohort even though the
CRT cohort is chronologically older. There are a couple
of key reasons for this difference in follow- up. First, this
study spanned a lengthy period, from 2004 through 2015.
During the early portions of the study period, multiple
transitions occurred in providers taking care of patients
with a diagnosis of breast cancer at our institution. As
such, follow-up during this period suffered owing to lack
of patients returning to the clinic given their primary ra-
diation oncologist was no longer present. These transi-
tions were not present in the latter half of the study period,
which is when IMRT was used in our clinic. Another
shortcoming of the earlier half of the study period was the
lack of a unified electronic medical record system.
Follow-ups for patients may have occurred at neighboring
clinics and institutions, but these outside records were not
easily available for review. With our modern electronic
medical record, patients can easily provide consent for
outside records to be brought into the system and this has
extended the available follow-up period. Once again, this
favored the follow-up length for the IMRT cohort. Even
with these limitations, this study provided a thorough
evaluation of the risk of RIBP in the setting of compre-
hensive adjuvant RT for breast cancer using modern
treatment techniques.
Conclusions
In summary, RIBP is a rare but devastating conse-
quence of comprehensive adjuvant RT. Our study did not
identify any dosimetric predictors for RIBP given the
rarity of this outcome, but the rate of RIBP in our cohort
compared well with prior data from conventionally treated
breast cancer cohorts. Common factors for RIBP included
ALND and the use of PAB fields among patients
receiving CRT. IMRT did not increase risk for develop-
ment of RIBP. Studies evaluating IMRT technique in
cohorts with prospectively collected toxicity data are
needed to establish whether IMRT can reduce the inci-
dence of RIBP for comprehensive adjuvant RT.














A 40.8 49.7 63.2 46.0 0 0
B 46.7 54.0 93.5 73.9 27.1 0
C 47.1 56.0 90.5 85 46.2 0.6
D 49.4 65.1 81.5 79.7 76.1 54.4
E 40.3 57.2 69.9 65.2 52.5 4.3
Median
values
46.7 56.0 81.5 73.9 46.2 0.6













A1 39.3 54.3 70.7 61.1 22 0
A2 43.8 60.0 80.5 75.7 55.2 3.3
B1 38.7 54.3 73.6 71.4 30.2 0
B2 39.6 53.2 76.9 57.3 3.4 0
C1 44.3 54.9 80.8 78.1 65.2 0
C2 44.3 57.8 77.4 75.1 69.0 17.3
D1 40.4 60.5 68.2 66.5 61.6 44.4
D2 33.3 47.4 54.7 1.4 0 0
E1 44.7 54.7 83.1 77.5 47.8 0
E2 35.3 57.9 62.4 58.7 40.2 15.7
Median
values
40.0 54.8 75.3 69.0 44 0













AA1 40.2 55.4 70.3 65.6 47.5 0.2
AA2 49.7 57.3 93.3 92.1 73.6 3.5
BB1 43.3 54.3 76.9 73.4 68.6 0
BB2 41.5 56.0 74.0 68.7 61.2 2.1
CC1 48.8 54.6 88.8 85.6 74.0 0
CC2 44.9 54.2 75.6 71.1 66.0 0
DD1 45.6 54.9 80.3 72.9 64.3 0
DD2 49.0 54.3 93.3 89.5 59.1 0
EE1 38.9 52.6 60.3 56.1 43.3 0
EE2 37.8 55.8 65.5 60.8 44.6 0.6
Median
values
44.1 54.8 76.3 72 63 0
Abbreviations: 3D-CRT Z 3-dimensional conventional radiation
therapy; IMRT Z intensity modulated RT; RIBP Z radiation-
induced brachial plexopathy; RT Z radiation therapy.
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